Efficacy and Safety of Certolizumab Pegol for Crohn’s Disease: A Systematic Review and Meta-Analysis
- First Online:
- Cite this article as:
- Da, W., Zhu, J., Wang, L. et al. Adv Ther (2013) 30: 541. doi:10.1007/s12325-013-0026-3
- 439 Downloads
The authors performed a systematic review and meta-analysis of data from randomized controlled trials (RCTs) to evaluate the efficacy and safety of certolizumab pegol.
The authors searched PubMed, MEDLINE via Medscape, BioMed Central, Google Scholar, China National Knowledge Infrastructure (CNKI), the Cochrane library, and the Directory of Open Access Journals. The outcomes of interest were response and remission rates and the treatment-related toxicity rate.
A total of five RCTs, involving 1,891 participants, were included. The meta-analysis revealed that certolizumab significantly increased the overall (induction + maintenance therapy) response [odds ratio (OR) 1.565, 95% CI 1.056–2.321, P = 0.026] and remission rates (OR 1.626, 95% CI 1.297–2.038, P < 0.001) compared with placebo. Certolizumab significantly increased the response and remission rates when given as maintenance therapy (OR 2.171, 95% CI 1.644–2.866, P < 0.001 and OR 1.888, 95% CI 1.390–2.565, P < 0.001), but not as induction therapy (OR 1.234, 95% CI 0.912–1.671, P = 0.173 and OR 1.361, 95% CI 0.974–1.901, P = 0.071). Certolizumab (induction + maintenance therapy) did not significantly increase the treatment-related toxicity rate compared with placebo (OR 0.985, 95% CI 0.799–1.214, P = 0.887).
Certolizumab may be an efficacious treatment for Crohn’s disease as maintenance therapy and appears to have a favorable safety profile.